Suppr超能文献

非酒精性脂肪性肝病中补充亚麻籽粉:一项随机对照临床试验。

Flaxseed powder supplementation in non-alcoholic fatty liver disease: a randomized controlled clinical trial.

作者信息

Tian Yanyan, Zhou Yuhao, Liao Wang, Xia Jiayue, Hu Qiaosheng, Zhao Qing, Zhang Rui, Sun Guiju, Yang Ligang, Li Lihua

机构信息

Key Laboratory of Environmental Medicine and Engineering of Ministry of Education, and Department of Nutrition and Food Hygiene, School of Public Health, Southeast University, Nanjing 210009, China.

Lianshui People's Hospital Affiliated to Kangda College of Nanjing Medical University, Huai'an, Jiangsu, 223400, China.

出版信息

Food Funct. 2025 Feb 17;16(4):1389-1406. doi: 10.1039/d4fo05847j.

Abstract

: Non-alcoholic fatty liver disease (NAFLD) has become a growing public health problem worldwide, and dietary interventions have important potential in the prevention and treatment of NAFLD. Moreover, previous animal studies have shown that flaxseed has a good improvement effect in animal NAFLD models. : Assess whether flaxseed powder could improve the liver lipid content in patients with NAFLD. : In this 12-week randomized controlled clinical trial, 50 patients were randomly assigned to the flaxseed group ( = 25) and the control group ( = 25). The flaxseed group received 30 g d flaxseed powder orally before lunch or dinner along with health education, while the control group received only health education. The primary outcome was the intrahepatic lipid content assessed by the proton density fat fraction estimated by magnetic resonance imaging, and secondary outcomes were body composition measurements, liver function, and glucolipid metabolism. : Patients in the flaxseed group showed significantly lower liver fat content, body fat percentage, obesity index, visceral fat area, serum total bilirubin (TBIL), direct bilirubin (DBIL), indirect bilirubin (IBIL), aspartate aminotransferase (AST), total cholesterol (TC), and triglyceride (TG) levels after a 12-week intervention compared to pre-intervention levels, while serum apolipoprotein A1 (Apo A1) and high-density lipoprotein cholesterol (HDL-C) levels were significantly increased, with all differences being statistically significant ( < 0.05). Analysis of the gut microbiota showed that, at the phylum level, flaxseed intervention significantly increased the abundance of and , while decreasing the ratio of to . At the genus level, the relative abundance of , , , , and in the gut microbiota of the flaxseed group was significantly higher than that of the control group ( < 0.05), whereas the relative abundance of was significantly lower than that of the control group ( < 0.05). : Flaxseed powder intervention for 12 weeks had the effect of improving liver lipid deposition, liver function, body composition indicators, and lipid metabolism in patients with NAFLD. It also regulated the gut microbiota in NAFLD patients, increasing the abundance of beneficial bacteria while reducing harmful bacteria. This suggested that flaxseed is one of the natural and effective foods for improving NAFLD.

摘要

非酒精性脂肪性肝病(NAFLD)已成为全球日益严重的公共卫生问题,饮食干预在NAFLD的预防和治疗中具有重要潜力。此外,先前的动物研究表明,亚麻籽对动物NAFLD模型有良好的改善作用。:评估亚麻籽粉是否能改善NAFLD患者的肝脏脂质含量。:在这项为期12周的随机对照临床试验中,50例患者被随机分为亚麻籽组(n = 25)和对照组(n = 25)。亚麻籽组在午餐或晚餐前口服30 g/d亚麻籽粉并接受健康教育,而对照组仅接受健康教育。主要结局是通过磁共振成像估计的质子密度脂肪分数评估的肝内脂质含量,次要结局是身体成分测量、肝功能和糖脂代谢。:与干预前水平相比,亚麻籽组患者在12周干预后肝脏脂肪含量、体脂百分比、肥胖指数、内脏脂肪面积、血清总胆红素(TBIL)、直接胆红素(DBIL)、间接胆红素(IBIL)、天冬氨酸转氨酶(AST)、总胆固醇(TC)和甘油三酯(TG)水平显著降低,而血清载脂蛋白A1(Apo A1)和高密度脂蛋白胆固醇(HDL-C)水平显著升高,所有差异均有统计学意义(P < 0.05)。肠道微生物群分析表明,在门水平上,亚麻籽干预显著增加了拟杆菌门和厚壁菌门的丰度,同时降低了拟杆菌门与厚壁菌门的比例。在属水平上,亚麻籽组肠道微生物群中双歧杆菌属、罗氏菌属、粪球菌属、瘤胃球菌属和真杆菌属的相对丰度显著高于对照组(P < 0.05),而嗜胆菌属的相对丰度显著低于对照组(P < 0.05)。:亚麻籽粉干预12周对NAFLD患者有改善肝脏脂质沉积、肝功能、身体成分指标和脂质代谢的作用。它还调节了NAFLD患者的肠道微生物群,增加了有益菌的丰度,同时减少了有害菌。这表明亚麻籽是改善NAFLD的天然有效食物之一。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验